Thrivebio
Beverly, US · Founded 2014 · Delaware corporation · 1 known investors
Find your way into Thrivebio
317 people in our graph share verified history with the Thrivebio team — schools, employers, funds. One of them is your warm intro.
Charles Callunlockedknows Gary Paul Magnant · together at Montana State University-Bozeman (overlapped)
×4knows the team · via Harvard University
×2knows the team · via Dana-Farber Cancer Institute
×2knows the team · via Fair Isaac Corporation (FICO)
×2knows the team · via Montana State University-Bozeman
knows the team · via University of Massachusetts Dartmouth
Thrive Bioscience develops the Thrive IQ software platform and CellAssist imaging systems that capture and analyze time-series morphological data on live cells, colonies, and organoids in culture. Its products produce ML/AI-ready phenotypic data sets for biologists and data scientists working in cell biology and bioprocessing.
Founders & leadership
TF
Thomas Forest FarbinCEO, President and Board Member at Thrive Bioscience, Inc.Thomas Forest Farb is co-founder and president of Thrive Bioscience. Previously, he held executive roles including president and COO of Indevus Pharmaceuticals, EVP and CFO of Interneuron Pharmaceuticals, and CFO of Cytyc Corporation, and has served on the boards of several life sciences and technology companies.
GP
Gary Paul MagnantinCEO2014–2015Gary Paul Magnant co-founded and previously led Thrive Bioscience, Sage Science, and Owl Scientific (acquired by Thermo Fisher), and held executive roles at MJ Research (now Bio-Rad); he is currently a General Partner at Formation Venture Engineering funds.
MF
AP
Alan Philippe BlanchardNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$14.4M disclosed across 4 rounds · 2015–2017
▶$1.8MraisedAug 2017 · 21 investors · BiotechnologyRule 506(b)
▶$1.8MraisedAug 2017 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Forest FarbExecutive Officer, Director
- Michael FinneyDirector
- Brock ReeveDirector
- Alan Philippe BlanchardExecutive Officer, Director
- Guy BroadbentDirector
- Offering amount
- $2.5M
- Amount sold
- $1.8M
- Minimum investment
- $100K
- Proceeds to insiders
- $264K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$7.2MraisedMar 2017 · 36 investors · BiotechnologyRule 506(b)
▶$7.2MraisedMar 2017 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan Philippe BlanchardExecutive Officer, Director
- Michael FinneyDirector
- Thomas Forest FarbExecutive Officer, Director
- Brock ReeveDirector
- Guy BroadbentDirector
- Offering amount
- $10M
- Amount sold
- $7.2M
- Minimum investment
- $7.5K
- Proceeds to insiders
- $760K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$2.2MraisedDec 2015 · 20 investors · BiotechnologyRule 506(b)
▶$2.2MraisedDec 2015 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan Philippe BlanchardExecutive Officer, Director
- Michael FinneyDirector
- Thomas Forest FarbExecutive Officer, Director
- Brock ReeveDirector
- Guy BroadbentDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Minimum investment
- $7.5K
- Proceeds to insiders
- $350K
- First sale
- Nov 2015
- Incorporated
- Corporation, Massachusetts, 2014
- Federal exemptions
- 06b
▶$3.3MraisedMay 2015 · 24 investors · BiotechnologyRule 506(b)
▶$3.3MraisedMay 2015 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Forest FarbExecutive Officer, Director
- Michael Forest FinneyDirector
- Gary Paul MagnantExecutive Officer, Director
- Alan Philippe BlanchardExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $3.3M
- Minimum investment
- $20K
- Proceeds to insiders
- $285K
- First sale
- Apr 2015
- Incorporated
- Corporation, Massachusetts, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Agilent16 shared keywordsAgilent manufactures laboratory instruments, software, reagents, and consumables for pharmaceutical, diagnostics, clinical research, and applied markets including chemicals, food, and environmental sectors. The company operates through three segments: Life Sciences and Diagnostics Markets (which includes contract manufacturing services for oligonucleotide therapeutics and pathology solutions), Agilent CrossLab (providing lab services and automation), and Applied Markets (offering analytical instruments and software).
Leica Microsystems16 shared keywordsLeica Microsystems manufactures optical microscopy instruments and fluorescence reagents for scientific research and diagnostics. The company serves laboratories, research institutions, and diagnostic facilities requiring advanced imaging and analytical equipment.
Cell Microsystems15 shared keywordsCell Microsystems develops automated instruments for cellular and molecular workflows used in life science research, including oncology, stem cell biology, and regenerative medicine. Its products support scientists in laboratory research and single-cell isolation and analysis.
Companies competing with Thrivebio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Thrivebio do?
- Thrive Bioscience develops the Thrive IQ software platform and CellAssist imaging systems that capture and analyze time-series morphological data on live cells, colonies, and organoids in culture. Its products produce ML/AI-ready phenotypic data sets for biologists and data scientists working in cell biology and bioprocessing.
- Who are Thrivebio's investors?
- Thrivebio's investors include Lauder Partners.
- How much funding has Thrivebio raised?
- Thrivebio has disclosed $14.4M raised across 4 rounds.
- Where is Thrivebio headquartered?
- Thrivebio is headquartered in Beverly, US.